专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100099658A1 DI(ARYLAMINO)ARYL COMPOUND 有权
标题翻译： DI（ARYLAMINO）ARYL化合物
公开(公告)号：US20100099658A1
公开(公告)日：2010-04-22
申请号：US12448759
申请日：2008-07-04
申请人： Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
发明人： Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
IPC分类号： A61K31/397 , C07D239/72 , A61K31/497 , A61K31/517 , C07D413/02 , A61K31/5377 , C07D403/02 , A61K31/53 , C07D279/12 , A61K31/541 , A61P35/00
CPC分类号： A61K31/551 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K31/541 , C07D239/95 , C07D251/18 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/70 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/08 , C07D491/113 , C07D498/10
摘要： The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
摘要翻译：本发明提供了可用作抑制EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性的化合物。作为对具有对EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性具有抑制作用的化合物的广泛和深入研究的结果，本发明的发明人已经发现本发明的二（芳基氨基）芳基化合物具有对EML4-ALK融合蛋白和突变型EGFR蛋白激酶活性的抑制活性。这一发现导致了本发明的完成。本发明的化合物可以用作预防和/或治疗癌症，肺癌，非小细胞肺癌，小细胞肺癌，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸的药物组合物，阳性癌症，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性肺癌或EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性非小细胞肺癌等。

2. 发明申请

US20130096100A1 DI(ARYLAMINO)ARYL COMPOUND 审中-公开
标题翻译： DI（ARYLAMINO）ARYL化合物
公开(公告)号：US20130096100A1
公开(公告)日：2013-04-18
申请号：US13618732
申请日：2012-09-14
申请人： Yutaka KONDOH , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
发明人： Yutaka KONDOH , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
IPC分类号： A61K31/551 , A61K31/541 , A61K31/53 , A61K31/517 , A61K31/5377
CPC分类号： A61K31/551 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K31/541 , C07D239/95 , C07D251/18 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/70 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/08 , C07D491/113 , C07D498/10
摘要： The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
摘要翻译：本发明提供了可用作抑制EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性的化合物。作为对具有对EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性具有抑制作用的化合物的广泛和深入研究的结果，本发明的发明人已经发现本发明的二（芳基氨基）芳基化合物具有对EML4-ALK融合蛋白和突变型EGFR蛋白激酶活性的抑制活性。这一发现导致了本发明的完成。本发明的化合物可以用作预防和/或治疗癌症，肺癌，非小细胞肺癌，小细胞肺癌，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸的药物组合物，阳性癌症，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性肺癌或EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性非小细胞肺癌等。

3. 发明授权

US08318702B2 Di(arylamino)aryl compounds 有权
标题翻译：二（芳基氨基）芳基化合物
公开(公告)号：US08318702B2
公开(公告)日：2012-11-27
申请号：US12448759
申请日：2008-07-04
申请人： Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
发明人： Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
IPC分类号： A01N57/00 , A01N43/00 , A01N43/66 , A61K31/675 , A61K31/00 , A61K31/53 , C07D251/00 , C07D253/00 , C07D251/40 , C07D251/18 , C07D251/48
CPC分类号： A61K31/551 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K31/541 , C07D239/95 , C07D251/18 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/70 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/08 , C07D491/113 , C07D498/10
摘要： The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
摘要翻译：本发明提供了可用作抑制EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性的化合物。作为对具有对EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性具有抑制作用的化合物的广泛和深入研究的结果，本发明的发明人已经发现本发明的二（芳基氨基）芳基化合物具有对EML4-ALK融合蛋白和突变型EGFR蛋白激酶活性的抑制活性。这一发现导致了本发明的完成。本发明的化合物可以用作预防和/或治疗癌症，肺癌，非小细胞肺癌，小细胞肺癌，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸的药物组合物，阳性癌症，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性肺癌或EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性非小细胞肺癌等。

4. 发明申请

US20120040968A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND 有权
标题翻译： DIAMINO杂环碳酰胺化合物
公开(公告)号：US20120040968A1
公开(公告)日：2012-02-16
申请号：US13266164
申请日：2010-05-06
申请人： Itsuro Shimada , Kazuo Kurosawa , Takahiro Matsuya , Kazuhiko Iikubo , Yutaka Kondoh , Akio Kamikawa , Hiroshi Tomiyama , Yoshinori Iwai
发明人： Itsuro Shimada , Kazuo Kurosawa , Takahiro Matsuya , Kazuhiko Iikubo , Yutaka Kondoh , Akio Kamikawa , Hiroshi Tomiyama , Yoshinori Iwai
IPC分类号： A61K31/497 , C07D405/14 , C07D401/14 , C07D491/113 , C07D403/12 , A61K31/551 , A61K31/538 , C07D409/14 , C07D417/12 , A61K31/55 , A61K31/541 , C07D471/08 , C07D241/28 , C07D401/12 , A61K31/513 , C07D239/48 , A61P35/00 , A61K31/5377
CPC分类号： C07D239/48 , C07D241/26 , C07D241/28 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/08 , C07D491/113
摘要： Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein.As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
摘要翻译：提供了可用作抑制EML4-ALK融合蛋白的激酶活性的化合物。作为对具有针对EML4-ALK融合蛋白的激酶活性的抑制活性的化合物进行了深入和广泛的研究的结果，本发明人发现本发明的二氨基杂环羧酰胺化合物对EML4-ALK融合体的激酶活性具有抑制活性蛋白。通过这一发现，完成了本发明。本发明的化合物可以用作预防和/或治疗癌症的药物组合物，例如肺癌，非小细胞肺癌和小细胞肺癌。

5. 发明授权

US08969336B2 Diamino heterocyclic carboxamide compound 有权
标题翻译：二氨基杂环羧酰胺化合物
公开(公告)号：US08969336B2
公开(公告)日：2015-03-03
申请号：US13266164
申请日：2010-05-06
申请人： Itsuro Shimada , Kazuo Kurosawa , Takahiro Matsuya , Kazuhiko Iikubo , Yutaka Kondoh , Akio Kamikawa , Hiroshi Tomiyama , Yoshinori Iwai
发明人： Itsuro Shimada , Kazuo Kurosawa , Takahiro Matsuya , Kazuhiko Iikubo , Yutaka Kondoh , Akio Kamikawa , Hiroshi Tomiyama , Yoshinori Iwai
IPC分类号： A61K31/55 , A61K31/497 , A61K31/4965 , A61K31/505 , A61K31/54 , C07D243/08 , C07D413/14 , C07D241/02 , C07D237/02 , C07D401/12 , C07D239/48 , C07D241/26 , C07D241/28 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/08 , C07D491/113
CPC分类号： C07D239/48 , C07D241/26 , C07D241/28 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/08 , C07D491/113
摘要： Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein.As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
摘要翻译：提供了可用作抑制EML4-ALK融合蛋白的激酶活性的化合物。作为对具有针对EML4-ALK融合蛋白的激酶活性的抑制活性的化合物进行了深入和广泛的研究的结果，本发明人发现本发明的二氨基杂环羧酰胺化合物对EML4-ALK融合体的激酶活性具有抑制活性蛋白。通过这一发现，完成了本发明。本发明的化合物可以用作预防和/或治疗癌症的药物组合物，例如肺癌，非小细胞肺癌和小细胞肺癌。

6. 发明申请

US20130054392A1 SALES DATA PROCESSING DEVICE, SALES DATA PROCESSING METHOD AND COMPUTER READABLE STORAGE MEDIUM 有权
标题翻译：销售数据处理设备，销售数据处理方法和计算机可读存储介质
公开(公告)号：US20130054392A1
公开(公告)日：2013-02-28
申请号：US13569434
申请日：2012-08-08
申请人： Kazuo Kurosawa
发明人： Kazuo Kurosawa
IPC分类号： G06Q30/00
CPC分类号： G07G1/0009 , G07G3/006
摘要： A sales data processing device of the present invention accepts operations by an operator, opens a drawer, and is provided with a history acquisition unit, a reference information acquisition unit and an irregularity detection unit. The history acquisition unit acquires a history of operations by the operator. The reference information acquisition unit acquires, from references of standard operations set in advance for each of operations that cause the drawer to open, the standard operation references for operations specified in the history. For each of the operations specified in the history, the irregularity detection unit finds a difference from the standard operation reference acquired by the reference information acquisition unit, and if the difference is of at least a predetermined level, detects that the operation is an irregular drawer operation.
摘要翻译：本发明的销售数据处理装置接受操作者的操作，打开抽屉，并具有历史获取单元，参考信息获取单元和不规则检测单元。历史获取单元获取操作员的操作历史。参考信息获取单元从为引起抽屉打开的每个操作预先设定的标准操作的参考中获取历史中指定的操作的标准操作参考。对于历史中指定的每个操作，不规则检测单元发现与由参考信息获取单元获取的标准操作参考值的差异，并且如果差值至少为预定水平，则检测到该操作是不规则抽屉操作。

7. 发明授权

US09449474B2 Sales data processing device, sales data processing method and computer readable storage medium 有权
标题翻译：销售数据处理装置，销售数据处理方法和计算机可读存储介质
公开(公告)号：US09449474B2
公开(公告)日：2016-09-20
申请号：US13569434
申请日：2012-08-08
申请人： Kazuo Kurosawa
发明人： Kazuo Kurosawa
IPC分类号： G06Q20/00 , G07G1/00 , G07G3/00
CPC分类号： G07G1/0009 , G07G3/006
摘要： A sales data processing device of the present invention accepts operations by an operator, opens a drawer, and is provided with a history acquisition unit, a reference information acquisition unit and an irregularity detection unit. The history acquisition unit acquires a history of operations by the operator. The reference information acquisition unit acquires, from references of standard operations set in advance for each of operations that cause the drawer to open, the standard operation references for operations specified in the history. For each of the operations specified in the history, the irregularity detection unit finds a difference from the standard operation reference acquired by the reference information acquisition unit, and if the difference is of at least a predetermined level, detects that the operation is an irregular drawer operation.
摘要翻译：本发明的销售数据处理装置接受操作者的操作，打开抽屉，并具有历史获取单元，参考信息获取单元和不规则检测单元。历史获取单元获取操作员的操作历史。参考信息获取单元从为引起抽屉打开的每个操作预先设定的标准操作的参考中获取历史中指定的操作的标准操作参考。对于历史中指定的每个操作，不规则检测单元发现与由参考信息获取单元获取的标准操作参考值的差异，并且如果差值至少为预定水平，则检测到该操作是不规则抽屉操作。

8. 发明申请

US20090082367A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF 审中-公开
标题翻译：三唑衍生物或其盐
公开(公告)号：US20090082367A1
公开(公告)日：2009-03-26
申请号：US12293214
申请日：2007-03-14
申请人： Seiji Yoshimura , Ryota Shiraki , Tomoaki Kawano , Daisuke Sasuga , Mitsuru Hosaka , Hiroki Fukudome , Kazuo Kurosawa , Hirofumi Ishii , Takanori Koike
发明人： Seiji Yoshimura , Ryota Shiraki , Tomoaki Kawano , Daisuke Sasuga , Mitsuru Hosaka , Hiroki Fukudome , Kazuo Kurosawa , Hirofumi Ishii , Takanori Koike
IPC分类号： A61K31/4196 , C07D401/06 , A61K31/4439 , A61K31/497 , A61P3/10 , A61K31/4709 , C07D403/06
CPC分类号： C07D249/08 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/08 , C07D409/06 , C07D409/08 , C07D409/12 , C07D413/06 , C07D417/06
摘要： [Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance.[Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11β-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.
摘要翻译： [问题]提供可用于治疗其中涉及11β-羟类固醇脱氢酶1型（11beta-HSD1）的疾病的化合物，特别是糖尿病和胰岛素抵抗。 [解决方法]发现三唑环的3-位被三取代甲基取代的三唑衍生物或其药学上可接受的盐，并且5位被低级烷基，环烷基或具有强的11beta-HSD1抑制活性。此外，由于本发明的三唑衍生物显示出优异的降血糖作用，因此可用于治疗糖尿病和胰岛素抵抗。

9. 发明授权

US07093137B1 Database management apparatus and encrypting/decrypting system 有权
标题翻译：数据库管理装置及加密/解密系统
公开(公告)号：US07093137B1
公开(公告)日：2006-08-15
申请号：US09670424
申请日：2000-09-26
申请人： Makoto Sato , Tsuneharu Takeda , Junji Mori , Kazuo Kurosawa
发明人： Makoto Sato , Tsuneharu Takeda , Junji Mori , Kazuo Kurosawa
IPC分类号： G06F11/30
CPC分类号： G06F21/6227 , Y10S707/99936
摘要： In a database, a frequently retrieved column is encrypted using a common key, and other columns are encrypted using a specific row key. Thus, a retrieving process can be performed at a high speed, and the security can be improved. Then, the row and column of the database are encrypted by assuming the plaintext to be encrypted as a bit string, and performing a binary operation with a random bit string. A random bit string is obtained by sequentially generating multidimensional vectors using a nonlinear function by defining a predetermined bit length as 1 word and a plurality of words as components of the multidimensional vector.
摘要翻译：在数据库中，使用公共密钥对经常检索的列进行加密，并使用特定的行密钥对其他列进行加密。因此，可以高速执行检索处理，并且可以提高安全性。然后，数据库的行和列通过假定明文被加密为位串来进行加密，并且使用随机位串执行二进制操作。通过将预定比特长度定义为1个字和多个字作为多维向量的分量，通过使用非线性函数顺序生成多维向量来获得随机比特串。

10. 发明申请

US20060136278A1 Work management system 审中-公开
标题翻译：工作管理系统
公开(公告)号：US20060136278A1
公开(公告)日：2006-06-22
申请号：US11311677
申请日：2005-12-19
申请人： Motoi Otsuka , Kazuo Kurosawa
发明人： Motoi Otsuka , Kazuo Kurosawa
IPC分类号： G06F9/44
CPC分类号： G06Q10/10 , G06Q10/00 , G06Q10/0631
摘要： A headquarters manager's terminal is used to prepare work instruction information and to transfer the prepared information to a headquarters server, and the headquarters server sends the work instruction information to a mobile terminal through a store server. The mobile terminal is used to prepare work report information for reporting activities performed in accordance with the work instruction, and to send the headquarters server the work report information with a photographed image of work site attached to. The headquarter server arranges and stores the work instruction information and work report information accompanying the photographed image, both being associated with each other, in a work instruction information file. The headquarter manager's terminal reads out the work instruction information file to display the work report information associated with the work instruction information. The invention allows a person to work referring to the work instruction displayed on the mobile terminal, and also allows the manager to save processing effort in preparing work report information with a photographed image attached to. Since the work instruction information and work report information with a photographed image attached to are displayed in a correlated manner with each other on the manager's terminal, the manager can easily confirm a relationship between the work instruction information and work report information with the photographed image attached to.
摘要翻译：总部经理终端用于准备工作指导信息并将准备的信息传送到总部服务器，总部服务器通过商店服务器将工作指令信息发送到移动终端。移动终端用于根据工作指导准备报告活动的工作报告信息，并向总部服务器发送工作报告信息，并附上所附工作场所的拍照图像。总部服务器将工作指示信息和伴随拍摄图像的工作报告信息彼此相关联地存储在工作指令信息文件中。总部经理终端读出工作指导信息文件，显示与工作指令信息相关的工作报告信息。本发明允许一个人参照移动终端上显示的工作指令进行工作，并且还允许管理者节省用附加的拍摄图像准备工作报告信息的处理工作。由于在管理者的终端上以相关联的方式显示附带有拍摄图像的作业指示信息和工作报告信息，所以管理者可以容易地确认工作指示信息和工作报告信息之间的关系与附加的拍摄图像至。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式